Federal State Budget Institution "A.N. Bakulev National Medical Research Centre for Cardiovascular Surgery" of the Ministry of Healthcare of the Russian Federation (Bakulev NMRCCS), Moscow, Russian Federation,
Federal State Budget Institution "A.N. Bakulev National Medical Research Centre for Cardiovascular Surgery" of the Ministry of Healthcare of the Russian Federation (Bakulev NMRCCS), Moscow, Russian Federation.
Blood Purif. 2021;50(2):222-229. doi: 10.1159/000510126. Epub 2020 Nov 26.
To date, sepsis remains one of the main challenges of intensive care in pediatrics. Newborns with low birth weight and infants with chronic diseases and congenital disorders are particularly at risk. The incidence of infectious complications in pediatric cardiac surgery is known to be approximately 15-30%. The main etiological factor of sepsis is endotoxin.
To evaluate the efficiency and safety of polymyxin (PMX) B-immobilized column-direct hemoperfusion in complex intensive therapy of sepsis in children after cardiac surgery with cardiopulmonary bypass.
Prospective cohort study.
This study enrolled 15 children, aged 9-96 months, with congenital heart diseases and with body weights of 6.2-22.5 kg. The criteria for admission were body weight >6 kg and clinical and laboratory signs of sepsis (microbiological analysis, procalcitonin [PCT] >2 ng/mL, and endotoxin activity assay [ЕАА] >0.6). Intensive care included inotropic and vasopressor support, mechanical ventilation, broad-spectrum antibiotic therapy, and PMX hemoperfusion procedures. Extracorporeal therapy was initiated within 24 h following the sepsis diagnosis. Every patient underwent 2 hemoperfusion sessions with the use of a PMX B-immobilized column; the session duration was 180 min.
We noted improvements in hemodynamic parameters, oxygenation index, and laboratory signs of sepsis, with decreases in the endotoxin concentration according to the EAA, PCT, and presepsin levels. The 28-day survival of the patients in this severely affected group was 80%. Main Conclusion: The inclusion of extracorporeal methods of blood purification, aimed at the selective elimination of circulating endotoxin, in the treatment of sepsis increases the survival rates of children after open heart surgery. Second Conclusion: The obtained results of sepsis therapy with PMX hemoperfusion in children after cardiac surgery enable us to suggest the sufficient safety and efficiency of the procedures in this category of severely affected patients.
迄今为止,败血症仍然是儿科重症监护的主要挑战之一。低出生体重儿和患有慢性疾病及先天性疾病的婴儿风险尤其高。儿科心脏手术中感染并发症的发病率约为 15-30%。败血症的主要病因是内毒素。
评估聚马菌素(PMX)B 固定化柱直接血液灌流在体外循环心脏手术后儿童败血症复杂强化治疗中的疗效和安全性。
前瞻性队列研究。
这项研究纳入了 15 名年龄 9-96 个月、患有先天性心脏病且体重 6.2-22.5 公斤的儿童。入选标准为体重>6 公斤和有败血症的临床及实验室表现(微生物分析、降钙素原[PCT]>2ng/ml 和内毒素活性测定[ЕАА]>0.6)。强化治疗包括正性肌力和血管加压支持、机械通气、广谱抗生素治疗和 PMX 血液灌流。在诊断败血症后 24 小时内开始进行体外治疗。每位患者接受 2 次 PMX B 固定化柱血液灌流,每次 180 分钟。
我们观察到血流动力学参数、氧合指数和败血症的实验室指标得到改善,根据 ЕАА、PCT 和前降钙素水平,内毒素浓度降低。在这一严重感染组中,患者 28 天存活率为 80%。主要结论:在治疗败血症时,纳入旨在选择性清除循环内毒素的体外血液净化方法可提高心脏直视手术后儿童的生存率。次要结论:在心脏手术后儿童中使用 PMX 血液灌流治疗败血症获得的结果表明,这些方法在这一严重感染患者类别中具有足够的安全性和有效性。